Tenecteplase intra-arterioso dopo trombectomia endovascolare per ictus da occlusione di grandi vasi (TNK-FLOW)
The purpose of this study is to determine the safety and feasibility of using intra-arterial Tenecteplase in patients undergoing blood clot extraction for treatment of acute ischemic (non-bleeding) stroke. Intravenous Tenecteplase is FDA-approved to treat patients with an ischemic stroke presenting within the 0-3-hour time window.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
The primary objective of this study is to determine the safety and feasibility of intra-arterial Tenecteplase in selected patients with persistent post-thrombectomy hypoperfusion on computed tomography perfusion based on symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage producing decline from the initial NIHSS of ≥ 4 points) at 24-36 hours.
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28207
- Atrium Health Neurosciences Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patient/legally authorized representative has signed the Informed Consent Form
- Ability to comply with the study protocol, in the investigator's judgment
- Functionally independent (modified Rankin scale 0-2) prior to presentation
- Baseline National Institutes of Health Stroke Scale (NIHSS) ≥ 6
- Clinical syndrome consistent with occlusion of the internal carotid artery (ICA) or proximal middle cerebral artery (MCA), presenting within 4.5- to 24-hours of TLKW
- Evidence of ICA, MCA-M1, or MCA-M2 occlusion on baseline computed tomography angiogram (CTA) or magnetic resonance angiogram (MRA). ICA/MCA tandem occlusions may be enrolled
- Alberta Stroke Program Early Computed Tomography Score ≥ 6 on pre-thrombectomy unenhanced CT as determined by treating neurologist or reading radiologist
- Pre-thrombectomy CTP or MRP with core infarction (cerebral blood flow < 30%) < 70 ml, mismatch ratio ≥ 1.8, mismatch volume ≥ 15 ml (completed within 120 minutes of skin puncture for thrombectomy). If skin puncture occurs more than 120 minutes after the pre-thrombectomy CTP, enrollment may proceed at the PI's discretion.
- Endovascular thrombectomy of ICA, MCA-M1 or MCA-M2 occlusion performed according to local standard of care, defined as at least completing the initial diagnostic angiogram
- CTP performed with RAPID AI AngioFlowTM within 30 minutes of thrombectomy completion
- Modified thrombolysis in cerebral infarction (mTICI) 2b-3 revascularization following endovascular thrombectomy (EVT) (or after initial diagnostic angiogram)
- Presence of Tm > 6 lesion on post-EVT CTP of adequate quality for interpretation in the distribution of the symptomatic occlusion
Exclusion Criteria:
- Current participation in another investigational drug or device study
- Known hypersensitivity or allergy to any ingredients of tenecteplase
- Active internal bleeding
- Known bleeding diathesis (e.g., Alzheimer's patients taking lecanemab)
- Systolic blood pressure > 185 mm Hg or diastolic blood pressure > 110 mm Hg after EVT, refractory to medical therapy
- Known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency; recent oral anticoagulant therapy with INR > 1.7
- Use of one of the new oral anticoagulants within the last 48 hours (dabigatran, rivaroxaban, apixaban, edoxaban)
- Treatment with a thrombolytic within the last 3 months prior to randomization
- Baseline platelet count < 100,000/mcL (results must be available prior to treatment)
- Baseline blood glucose > 400 mg/dL (22.20 mmol/L)
- Baseline blood glucose < 50 mg/dL; needs to be normalized prior to randomization
- Intracranial or intraspinal surgery or trauma within 2 months
- Intracranial malignant neoplasm, arteriovenous malformation, or unsecured aneurysm > 1 cm
- Other serious, advanced, or terminal illness (investigator's judgment) or life expectancy is less than 6 months
- History of acute ischemic stroke in the last 90 days
- History of hemorrhagic stroke
- Presumed septic embolus; suspicion of bacterial endocarditis
- Any other condition that, in the opinion of the investigator, precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was to be performed
- Pregnant
- Acute intracranial hemorrhage on pre-thrombectomy imaging or suspected acute intracranial hemorrhage after EVT
- Acute bilateral strokes on initial imaging
- Multiple acute intracranial occlusions (except ICA/MCA) on initial CTA or MRA
- Significant hemispheric mass effect or any amount of midline shift due to acute stroke
- Placement of cervical carotid or intracranial stent during thrombectomy procedure requiring dual antiplatelet therapy
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Intra-arterial Tenecteplase
Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of intra-arterial Tenecteplase (0.125 mg/kg, maximum dose 12.5 mg) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
One-time dose of intra-arterial tenecteplase post-thrombectomy |
|
Comparatore placebo: Intra-arterial Saline
Following endovascular thrombectomy for large vessel occlusion stroke one-time dose of saline (0.9% NaCl solution) will be delivered over 5-10 seconds by the treating neuro-interventionalist through a microcatheter positioned as close as possible to the residual thrombus or as distal as possible in the originating vessel, per the discretion of the neuro-interventionalist. |
One-time dose of intra-arterial saline post-thrombectomy |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Participants with Change in Symptomatic Intracranial Hemorrhage
Lasso di tempo: Hour 36
|
Number of participants with symptomatic intracranial hemorrhage (parenchymal hematoma type 2, subarachnoid hemorrhage, and/or intraventricular hemorrhage) producing decline from the initial National Institutes of Health Stroke Scale (NIHSS) of ≥ 4 points. |
Hour 36
|
|
Participants with Parenchymal Hematoma Type 1
Lasso di tempo: 24 Hours
|
Number of participants with parenchymal hematoma type 1 |
24 Hours
|
|
Participants with Parenchymal Hematoma Type 2
Lasso di tempo: 24 Hours
|
Number of participants with parenchymal hematoma type 2 |
24 Hours
|
|
30-Day Mortality Count
Lasso di tempo: Day 30
|
Number of patients expired |
Day 30
|
|
90-Day Mortality Count
Lasso di tempo: Day 90
|
Number of patients expired |
Day 90
|
|
Number of Grade 3 Adverse Events
Lasso di tempo: Hour 24
|
Total number of grade 3 adverse events |
Hour 24
|
|
Number of Grade 3 Adverse Events
Lasso di tempo: Day 5
|
Total number of grade 3 adverse events |
Day 5
|
|
Number of Grade 3 Adverse Events
Lasso di tempo: Day 30
|
Total number of grade 3 adverse events |
Day 30
|
|
Number of Grade 3 Adverse Events
Lasso di tempo: Day 90
|
Total number of grade 3 adverse events |
Day 90
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Proportion of subjects achieving early neurological improvement
Lasso di tempo: Hour 24
|
Proportion of subjects achieving early neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2 |
Hour 24
|
|
Proportion of subjects achieving delayed neurological improvement
Lasso di tempo: Day 30, Day 90
|
Proportion of subjects achieving delayed neurological improvement, defined as National Institutes of Health Stroke Scale (NIHSS) reduction by ≥ 4 points or total NIHSS 0-2 |
Day 30, Day 90
|
|
Ordinal Modified Rankin Scale score
Lasso di tempo: Day 90
|
Modified Rankin scale scores range from 0-6. Higher score indicates greater disability. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-2 Points
Lasso di tempo: Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-2 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-1 Points
Lasso di tempo: Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-1 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Participants with Change in Modified Rankin Scale Score 0-3 Points
Lasso di tempo: Day 90
|
Number of participants with change in Modified Rankin Scale score of 0-3 points or return to baseline modified Rankin scale score. |
Day 90
|
|
Change in Infarct Volume
Lasso di tempo: Hour 24
|
Change in infarct volume on follow up CT or MRI |
Hour 24
|
|
Barthel Index Score
Lasso di tempo: Day 90
|
Number of participants with Barthel Index score ≥ 95. |
Day 90
|
|
Median EuroQol-5-Dimension (EQ-5D) Index
Lasso di tempo: Day 90
|
Median EuroQol-5-Dimension (EQ-5D) index has a score range of -0.573 to 1. Higher score indicates better quality score. |
Day 90
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Rahul Karamchandani, MD, Atrium Health Neurosciences Institute
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Disturbi cerebrovascolari
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Malattie vascolari
- Malattia cardiovascolare
- Processi patologici
- Emorragia
- Embolia e Trombosi
- Condizioni patologiche, segni e sintomi
- Ictus ischemico
- Ictus
- Trombosi
- Emorragie intracraniche
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IRB00121066
- 40010317 (Altro identificatore: Genentech, Inc)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .